Treatment of newly diagnosed advanced stage Hodgkin lymphoma

Blood Reviews

Volumn 26, Issue 4, 2012, Pages 167-174

  Uhm, Jieun ^a   Kuruvilla, John ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chemotherapy; Hodgkin lymphoma; Novel therapy; PET scan; Radiation

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTINOSTAT; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MOCETINOSTAT; PANOBINOSTAT; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ADVANCED CANCER; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DEATH; FATIGUE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; INFECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT CARE; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; PREDNISONE; PROCARBAZINE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; VINBLASTINE; VINCRISTINE;

EID: 84861480919     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.04.001     Document Type: Article

References (59)

1. Armitage J.O. Early-stage Hodgkin's lymphoma. N Engl J Med 2010, 363:653-662.
2. Duggan D.B., Petroni G.R., Johnson J.L., Glick J.H., Fisher R.I., Connors J.M., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003, 21:607-614.
3. Canellos G.P., Niedzwiecki D., Johnson J.L. Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med 2009, 361:2390-2391.
4. Canellos G.P., Anderson J.R., Propert K.J., Nissen N., Cooper M.R., Henderson E.S., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478-1484.
5. Diehl V., Franklin J., Pfreundschuh M., Lathan B., Paulus U., Hasenclever D., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003, 348:2386-2395.
6. Engert A., Diehl V., Franklin J., Lohri A., Dörken B., Ludwig W.-D., et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009, 27:4548-4554.
7. Behringer K., Breuer K., Reineke T., May M., Nogova L., Klimm B., et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's lymphoma study group. J Clin Oncol 2005, 23:7555-7564.
8. Eichenauer D.A., Haverkamp H., Behringer K., Halbsguth T., Fuchs M., Diehl V., et al. Secondary MDS/AML In Hodgkin Lymphoma Patients Treated within German Hodgkin Study Group (GHSG) Clinical Trials After Introduction of the BEACOPP Protocol. ASH Annual Meeting Abstracts 2010, 116. 2682-
9. Sieniawski M., Reineke T., Nogova L., Josting A., Pfistner B., Diehl V., et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008, 111:71-76.
10. Avigdor A., Bulvik S., Levi I., Dann E.J., Shemtov N., Perez-Avraham G., et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol 2010, 21:126-132.
11. Gallamini A., Hutchings M., Rigacci L., Specht L., Merli F., Hansen M., et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007, 25:3746-3752.
12. Gallamini A., Patti C., Viviani S., Rossi A., Fiore F., Di Raimondo F., et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011, 152:551-560.
13. Canellos G.P., Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002, 346:1417-1418.
14. Diehl V., Sieber M., Ruffer U., Lathan B., Hasenclever D., Pfreundschuh M., et al. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997, 8:143-148.
15. Ballova V., Ruffer J.U., Haverkamp H., Pfistner B., Muller-Hermelink H.K., Duhmke E., et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005, 16:124-131.
16. Federico M., Luminari S., Iannitto E., Polimeno G., Marcheselli L., Montanini A., et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009, 27:805-811.
17. Johnson P.W., Radford J.A., Cullen M.H., Sydes M.R., Walewski J., Jack A.S., et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005, 23:9208-9218.
18. Gobbi P.G., Levis A., Chisesi T., Broglia C., Vitolo U., Stelitano C., et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005, 23:9198-9207.
19. Horning S.J., Hoppe R.T., Breslin S., Bartlett N.L., Brown B.W., Rosenberg S.A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630-637.
20. Hoskin P.J., Lowry L., Horwich A., Jack A., Mead B., Hancock B.W., et al. Randomised comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009, 27:5390-5396.
21. Gordon L.I., Hong F., Fisher R.I., Bartlett N.L., Connors J.M., Gascoyne R.D., et al. A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496). ASH Annual Meeting Abstracts 2010, 116. 415-
22. Borchmann P., Haverkamp H., Diehl V., Cerny T., Markova J., Ho A.D., et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011, 29:4234-4242.
23. Engert A., Haverkamp H., Kobe C., Markova J., Renner C., Ho A.D., et al. Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin lymphoma: the GHSG HD15 final results. ASH Annual Meeting Abstracts 2011, 118:589. Abstract.
24. Gianni A.M., Rambaldi A., Zinzani P., Levis A., Brusamolino E., Pulsoni A., et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. J Clin Oncol (Meeting Abstracts) 2008, 26. 8506-
25. Viviani S., Zinzani P.L., Rambaldi A., Brusamolino E., Levis A., Bonfante V., et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011/07/22, 203-212. ed2011.
26. Chisesi T., Bellei M., Luminari S., Montanini A., Marcheselli L., Levis A., et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 2011, 29:4227-4233.
27. Proctor S.J., Mackie M., Dawson A., White J., Prescott R.J., Lucraft H.L., et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002, 38:795-806.
28. Federico M., Bellei M., Brice P., Brugiatelli M., Nagler A., Gisselbrecht C., et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003, 21:2320-2325.
29. Arakelyan N., Berthou C., Desablens B., de Guibert S., Delwail V., Moles M.P., et al. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Cancer 2008, 113:3323-3330.
30. Aleman B.M., Raemaekers J.M., Tomisic R., Baaijens M.H., Bortolus R., Lybeert M.L., et al. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2007, 67:19-30.
31. Kobe C., Dietlein M., Franklin J., Markova J., Lohri A., Amthauer H., et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008, 112:3989-3994.
32. Engert A., Kobe C., Markova J., Haverkamp H., Borchmann P., Hitz F., et al. Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial. ASH Annual Meeting Abstracts 2010, 116. 764-
33. Terasawa T., Lau J., Bardet S., Couturier O., Hotta T., Hutchings M., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009, 27:1906-1914.
34. Hasenclever D., Diehl V.A. prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998, 339:1506-1514.
35. Hutchings M., Mikhaeel N.G., Fields P.A., Nunan T., Timothy A.R. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005, 16:1160-1168.
36. Gallamini A., Rigacci L., Merli F., Nassi L., Bosi A., Capodanno I., et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006, 91:475-481.
37. Hutchings M., Loft A., Hansen M., Pedersen L.M., Buhl T., Jurlander J., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52-59.
38. Dann E.J., Bar-Shalom R., Tamir A., Haim N., Ben-Shachar M., Avivi I., et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007, 109:905-909.
39. Blum K.A., Johnson J.L., Niedzwiecki D., Cannellos G.P., Cheson B.D., Bartlett N.L., et al. A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206. Journal of Clinical Oncology 2006, 24:7576.
40. Kuruvilla J., Song K., Mollee P., Panzarella T., McCrae J., Nagy T., et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 2006, 11:25-29.
41. Little R., Wittes R.E., Longo D.L., Wilson W.H. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998, 16:584-588.
42. Pro B., Younes A., Albitar M., Dang N.H., Samaniego F., Romaguera J., et al. Thalidomide for patients with recurrent lymphoma. Cancer 2004, 100:1186-1189.
43. Younes A., Pro B., Romaguera J., Dang N. Safety and efficacy of Bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease. Blood 2004, 104:2638.
44. Blum K.A., Johnson J.L., Niedzwiecki D., Canellos G.P., Cheson B.D., Bartlett N.L. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007, 48:1313-1319.
45. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology 2009, 507-519.
46. Younes A., Romaguera J., Hagemeister F., McLaughlin P., Rodriguez M.A., Fiumara P., et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003, 98:310-314.
47. Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., et al. Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
48. Chen R., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Klasa R., et al. Results of a pivotal phase 2 study of Brentuximab Vendotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. ASH Annual Meeting Abstracts 2010, 116:283. Abstract.
49. Johnston P.B., Inwards D.J., Colgan J.P., Laplant B.R., Kabat B.F., Habermann T.M., et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010, 85:320-324.
50. Younes A., Ong T.-C., Ribrag V., Engert A., Ben-Yehuda D., McCabe R., et al. Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant. ASH Annual Meeting Abstracts 2009, 114. 923-
51. Sureda A., Younes A., Ben-Yehuda D., Ong T.-C., Kaufman J., Le Corre C., et al. Final Analysis: Phase II Study of Oral Panobinostat in Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant. ASH Annual Meeting Abstracts 2010, 116:419. Abstract.
52. Younes A., Hermandez F., Bociek R.G., Kasamon Y.L., Lee P., Gore L., et al. The HDAC Inhibitor Entinostat (SNDX-265) Induces Clinical Responses In Patients With Relapsed And Refractroy Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study. ASH Annual Meeting Abstracts 2011, 118:2715. Abstract.
53. Younes A., Oki Y., Bociek R.G., Kuruvilla J., Fanale M., Neelapu S., et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011, 12:1222-1228.
54. Fehniger T.A., Larson S., Trinkaus K., Siegel M.J., Cashen A.F., Blum K.A., et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011, 118:5119-5125.
55. Copeland A.R., Cao Y., Fanale M., Fayad L., McLaughlin P., Pro B., et al. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data. ASH Annual Meeting Abstracts 2009, 114. 1680-
56. Younes A., Connors J.M., Park S.I., Hunder N.N.H., Ansell S.M. Frontline therapy with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. ASH Annual Meeting Abstracts 2011, 118:955. Abstract.
57. Mendler J.H., Kelly J., Voci S., Marquis D., Rich L., Rossi R.M., et al. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008, 19:1759-1764.
58. Trelle S., Sezer O., Naumann R., Rummel M., Keller U., Engert A., et al. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica 2007, 92:568-569.
59. Johnson P.W.M., Horwich A., Jack A., Mead G., Hancock B., Smith P., et al. Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244. ASH Annual Meeting Abstracts 2008, 112. 370-